NCT01562405View on ClinicalTrials.gov

Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Multiple Myeloma
Interventions
DRUG

ACE-011

Injection every 28 days, dose escalation levels from 15-45 mg

DRUG

Lenalidomide

15 to 25 mg days 1-21, given orally

DRUG

Dexamethasone

40 mg days 1,8,15,22; given orally

DRUG

Pomalidomide

Pomalidomide 4 mg daily on days 1-21

Trial Locations (4)

30322

Emory University, Atlanta

02115

Massachusetts General Hosptial, Boston

02215

Brigham and Women's Hospital, Boston

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Multiple Myeloma Research Consortium

NETWORK

lead

Massachusetts General Hospital

OTHER